Political

No material political developments were reported this month for ASTH.

Regulatory and reimbursement exposure remains a structural consideration for a healthcare services business.

Economic

ASTH continues to show modest profitability with net profit margin at 1.1% and operating margin at 2.6%.

Valuation remains reasonable at 0.48x sales and 11.5x free cash flow, but leverage is still elevated with net debt to EBITDA at 3.3x.

Social

No new social or demand-shift news was reported this month.

Patient demand and utilization trends remain important to monitor, but fresh data did not indicate a material change.

Technological

No material technology or product-development updates were reported this month.

The business still appears operationally efficient, with fixed asset turnover at 37.8x and low capex intensity.

Legal

No new litigation or legal developments were reported this month.

Healthcare reimbursement and compliance risk remain ongoing legal overhangs.

Environmental

No material environmental developments were reported this month.

Environmental factors are not a primary driver for ASTH relative to other PESTLE categories.

Overall Score